Cite
Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis.
MLA
Wolf, Andrew B., and Enrique Alvarez. “Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis.” TouchREVIEWS in Neurology, vol. 18, no. 2, July 2022, pp. 117–21. EBSCOhost, https://doi.org/10.17925/USN.2022.18.2.117.
APA
Wolf, A. B., & Alvarez, E. (2022). Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis. TouchREVIEWS in Neurology, 18(2), 117–121. https://doi.org/10.17925/USN.2022.18.2.117
Chicago
Wolf, Andrew B., and Enrique Alvarez. 2022. “Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis.” TouchREVIEWS in Neurology 18 (2): 117–21. doi:10.17925/USN.2022.18.2.117.